Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KT-413 |
Synonyms | |
Therapy Description |
KT-413 degrades IRAK4, IKZF1 (Ikaros), and IKZF3 (Aiolos), potentially leading to tumor cell killing and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr LB118). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KT-413 | KT413|KT 413 | IRAK4 Inhibitor 7 | KT-413 degrades IRAK4, IKZF1 (Ikaros), and IKZF3 (Aiolos), potentially leading to tumor cell killing and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr LB118). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05233033 | Phase I | KT-413 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL | Suspended | USA | GBR | 0 |